Certolizumab

RED:

NICE TA375: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016).
NICE TA383: for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016).
NICE TA415: for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. (Decision date - November 2016).
NICE TA445: Certolizumab and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. (Decision date - June 2017).
NICE TA574: for treating moderate to severe plaque psoriasis. (Decision date - May 2019).

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)